The progress and development of biotechnology are opening up possibilities for the treatment and prevention of diseases that could only have been imagined in the past. Although many diseases and clinical trials are underway, but the stocks of these companies have attracted the attention of many investors.
At the same time, the penny stocks of biotech companies have become more concerned by investors than ever, some of them got a lot of money with these biotech stocks. And the prices of these biotech companies’s stocks may be further higher as new biotechnology breakthroughs go to public. However, you need to find them if you want to make money with these companies.
#1 Sunesis Pharmaceuticals Inc
Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, including its first-in-class PDK1 inhibitor SNS-510.
Back in November, Viracta and Sunesis announced the parties entered into a definitive merger agreement, The merger between the two companies is expected to close in the first quarter of 2021. The combined company will operate under the name Viracta Therapeutics, Inc. and intends to be listed on the Nasdaq Global Market under the ticker symbol “VIRX".
Viracta recently obtained a U.S. patent related to one of that company’s anti-cancer treatments. Which is good news before the merger with Sunesis. This news was likewise met with bullish investment into SNSS stock.
#2 Onconova Therapeutics Inc
Onconova is dedicated to developing new treatments for people with cancer. Its efforts are focused on disrupting key cellular pathways that play a role in cancer cell growth. Its treatment candidates are currently in early-stage trials.
The valuation of Onconova is about $370 millions, if the drugs developed by the company can achieve great success in the market, the upside potential is significant. Although the outlook is optimistic, but the therapy while promising is in very early stages and faces the long and risky clinical trial process.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.